TR201910410T4 - Endometriyal patolojilerde kök hücre terapisi. - Google Patents

Endometriyal patolojilerde kök hücre terapisi. Download PDF

Info

Publication number
TR201910410T4
TR201910410T4 TR2019/10410T TR201910410T TR201910410T4 TR 201910410 T4 TR201910410 T4 TR 201910410T4 TR 2019/10410 T TR2019/10410 T TR 2019/10410T TR 201910410 T TR201910410 T TR 201910410T TR 201910410 T4 TR201910410 T4 TR 201910410T4
Authority
TR
Turkey
Prior art keywords
endometrial
subject
bmdsc
autologous
stem cells
Prior art date
Application number
TR2019/10410T
Other languages
English (en)
Turkish (tr)
Inventor
SIMÓN Carlos
SANTAMARIA Javier
Pellicer Antonio
Cervello Irene
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of TR201910410T4 publication Critical patent/TR201910410T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
TR2019/10410T 2014-06-17 2015-06-05 Endometriyal patolojilerde kök hücre terapisi. TR201910410T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17

Publications (1)

Publication Number Publication Date
TR201910410T4 true TR201910410T4 (tr) 2019-08-21

Family

ID=54329860

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10410T TR201910410T4 (tr) 2014-06-17 2015-06-05 Endometriyal patolojilerde kök hücre terapisi.

Country Status (22)

Country Link
US (1) US11129851B2 (enExample)
EP (3) EP3158057B1 (enExample)
JP (2) JP6920062B2 (enExample)
CN (2) CN116747241A (enExample)
AU (1) AU2015275798B2 (enExample)
BR (1) BR112016029558A2 (enExample)
CA (1) CA2952559C (enExample)
CY (2) CY1122615T1 (enExample)
DK (2) DK3158057T3 (enExample)
ES (3) ES2983444T3 (enExample)
HR (3) HRP20240798T1 (enExample)
HU (3) HUE058328T2 (enExample)
LT (2) LT3158057T (enExample)
MX (1) MX377300B (enExample)
PL (3) PL3158057T3 (enExample)
PT (2) PT3158057T (enExample)
RS (3) RS63093B1 (enExample)
RU (1) RU2725006C2 (enExample)
SI (2) SI3158057T1 (enExample)
SM (3) SMT202400270T1 (enExample)
TR (1) TR201910410T4 (enExample)
WO (1) WO2015193737A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
KR102226219B1 (ko) 2012-06-06 2021-03-10 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 폐암 전이의 진단, 예후 및 치료 방법
JP6074049B2 (ja) 2012-10-12 2017-02-01 インバイオモーション エセ．エレ． ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140314792A1 (en) 2013-03-15 2014-10-23 Institució Catalana De Recerca I Estudis Avançats Method for the diagnosis, prognosis and treatment of cancer metastasis
HUE058328T2 (hu) 2014-06-17 2022-07-28 Asherman Therapy S L Õssejtterápia endometriális patológiás állapotokban
AU2017281631B2 (en) * 2016-06-23 2023-06-15 Tithon Biotech, Inc. Cells expressing parathyroid hormone 1 receptor and uses thereof
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
CN117979980A (zh) 2021-07-23 2024-05-03 车医科学大学校产学协力团 用于预防或治疗阿谢曼综合征的包含分离的线粒体作为活性成分的药物组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013299A1 (en) 1989-05-05 1990-11-15 Northern Sydney Area Health Service Fertility enhancement
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
AU2001240096A1 (en) 2000-03-08 2001-09-17 Rebecca L. Dubowy Methods of diagnosing and monitoring endometrial glandular development
JP2004504275A (ja) 2000-05-24 2004-02-12 シエーリング　アクチエンゲゼルシャフト フィブリン−１の医薬用途
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
EP1511863A4 (en) 2002-05-14 2006-12-27 Univ Leland Stanford Junior ENDOMETRIAL GENES FOR THE DETECTION OF ENDOMETRIAL DISORDERS
WO2004014935A1 (de) 2002-08-02 2004-02-19 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
EP1579007B1 (de) 2002-12-21 2015-05-27 Universität Leipzig Verfahren und mittel zur bestimmung von bestimmten zuständen bzw. veränderungen im uterusepithel und im epithel anderer organe
US20060286555A1 (en) 2003-08-21 2006-12-21 Van Beuningen Marinus G J Microarray support for bioprobe synthesis
CN1863905A (zh) 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
WO2005026324A2 (en) 2003-09-08 2005-03-24 The Board Of Regents Of The University Of Texas System Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog
US20080226554A1 (en) 2003-12-23 2008-09-18 Mount Sinai Hospital Methods For Detecting Markers Associated With Endometrial Disease or Phase
EP1765083A4 (en) 2004-05-28 2008-08-20 Serono Lab USE OF IL-17 TO TREAT FERTILITY DISORDERS
US20090111140A1 (en) * 2006-03-31 2009-04-30 Koninklijke Philips Electronics N.V. Systems and methods for cell measurement utilizing ultrashort t2*
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
EP2768976B1 (en) 2011-10-21 2018-01-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation
US9423402B2 (en) 2011-11-30 2016-08-23 Singapore Health Services Pte. Ltd. GM1 ganglioside to annexin V microparticle polypeptide ratio for biological monitoring
BR112014029233A8 (pt) 2012-06-27 2019-01-29 Hoffmann La Roche método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
WO2015166353A2 (en) 2014-03-21 2015-11-05 Equipo I. V. I. Investigacion S.L. Early detection of preeclampsia
HUE058328T2 (hu) 2014-06-17 2022-07-28 Asherman Therapy S L Õssejtterápia endometriális patológiás állapotokban

Also Published As

Publication number Publication date
US11129851B2 (en) 2021-09-28
MX2016016756A (es) 2017-11-02
US20170128492A1 (en) 2017-05-11
PT3569697T (pt) 2022-05-02
HRP20220419T1 (hr) 2022-05-27
CA2952559A1 (en) 2015-12-23
SMT202400270T1 (it) 2024-07-09
EP3158057B1 (en) 2019-04-17
JP2020138984A (ja) 2020-09-03
EP4012023C0 (en) 2024-05-15
RS59210B1 (sr) 2019-10-31
PL3158057T3 (pl) 2020-05-18
ES2910306T3 (es) 2022-05-12
RU2017101147A (ru) 2018-07-17
CY1125938T1 (el) 2024-02-16
JP2017522288A (ja) 2017-08-10
SMT202200155T1 (it) 2022-05-12
LT3569697T (lt) 2022-04-25
HUE044823T2 (hu) 2019-11-28
PT3158057T (pt) 2019-07-19
RS65719B1 (sr) 2024-08-30
EP4012023A1 (en) 2022-06-15
WO2015193737A1 (en) 2015-12-23
AU2015275798A1 (en) 2017-02-02
EP4012023B1 (en) 2024-05-15
MX377300B (es) 2025-03-07
LT3158057T (lt) 2019-09-25
EP3569697A1 (en) 2019-11-20
EP3569697B8 (en) 2022-04-27
AU2015275798B2 (en) 2021-03-25
RS63093B1 (sr) 2022-04-29
HUE058328T2 (hu) 2022-07-28
HRP20191240T1 (hr) 2019-11-01
SI3158057T1 (sl) 2019-10-30
SI3569697T1 (sl) 2022-05-31
RU2725006C2 (ru) 2020-06-29
DK3569697T3 (da) 2022-04-04
CA2952559C (en) 2023-01-24
HRP20240798T1 (hr) 2024-09-27
CN107073040A (zh) 2017-08-18
DK3158057T3 (da) 2019-07-29
CN116747241A (zh) 2023-09-15
CY1122615T1 (el) 2021-03-12
RU2017101147A3 (enExample) 2019-02-06
ES2983444T3 (es) 2024-10-23
SMT201900400T1 (it) 2019-09-09
PL3569697T3 (pl) 2022-07-04
BR112016029558A2 (pt) 2017-08-22
HUE067463T2 (hu) 2024-10-28
ES2736117T3 (es) 2019-12-26
EP3158057A1 (en) 2017-04-26
JP6920062B2 (ja) 2021-08-18
EP3569697B1 (en) 2022-01-05
PL4012023T3 (pl) 2024-09-02

Similar Documents

Publication Publication Date Title
TR201910410T4 (tr) Endometriyal patolojilerde kök hücre terapisi.
Zhao et al. Exosomes derived from adipose mesenchymal stem cells restore functional endometrium in a rat model of intrauterine adhesions
Gharibeh et al. Cell-based therapy in thin endometrium and Asherman syndrome
Zhang et al. Using 17β‐estradiol heparin‐poloxamer thermosensitive hydrogel to enhance the endometrial regeneration and functional recovery of intrauterine adhesions in a rat model
Aghajanova et al. Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience
Puente Gonzalo et al. Intrauterine infusion of platelet-rich plasma for severe Asherman syndrome: a cutting-edge approach
AU2016332771A1 (en) Pharmaceutical composition for improving ovarian function containing spheroid cell aggregate, and method for producing same
CN112870228B (zh) 一种多功能微环境保护外泌体水凝胶及其制备方法和应用
de Miguel‐Gómez et al. Strategies for managing Asherman's syndrome and endometrial atrophy: since the classical experimental models to the new bioengineering approach
Rageh et al. PRP in recurrent implantation failure, hope or hype? A prospective randomized controlled study
KR102190883B1 (ko) 불임증의 처치에 사용되는 의약 조성물 및 그 제조 방법
HK40099394A (zh) 子宫内膜病理状况中的干细胞治疗
KR20140041263A (ko) 말초혈액 단핵세포를 유효성분으로 포함하는 예방 또는 치료용 약제학적 조성물
HK40075844A (en) Stem cell therapy in endometrial pathologies
HK40075844B (en) Stem cell therapy in endometrial pathologies
HK1242600A1 (en) Stem cell therapy in endometrial pathologies
Costa Stem cell therapy to approach refractory Asherman’s syndrome
Santamaria et al. Hysteroscopy and Stem Cell Therapy to Approach Refractory Asherman’s Syndrome
Seifer et al. Stem cell therapies for atrophic endometrium and Asherman's syndrome
Delis AMD3100 Administration for the Treatment of Asherman’s Syndrome in a Murine Model
de Miguel Gómez et al. Stem Cell Transplantation for Endometrial Regeneration in Humans
Petta et al. Natural killer cells and telomerase in the endometrium of patients with endometriosis
Liu et al. Exogenous estrogen promotes regeneration of rat endometrial stromal cells
Hashish et al. Comparative Study Between the Differentiation Abilities of Placental Derived Stem Cells and Wharton Jelly Derived Stem Cells
Werkmeister Endometrial SUSD2+ Mesenchymal Stem/Stromal Cells in Tissue Engineering: Advances in Novel Cellular Constructs for Pelvic Organ Prolapse